Improving access to HIV/AIDS treatment in Brazil : when are compulsory licenses effective in price negotiations?

Abstract

People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.• The final author version and the galley proof are versions of the publication after peer review.• The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

When access to drugs meets catch-up: Insights from the use of CL threats to improve access to ARV drugs in Brazil

“…The availability of ARVs to people living with HIV/AIDS was to be ensured through local formulation of generic drugs in state-owned laboratories and imports of branded drugs from research-based pharmaceutical multinational enterprises (MNEs). It is worth noting that local production of ARVs in Brazil could be considered only because of prior catch-up in pharmaceuticals (Urias, 2015).…”